Recall of Viracept (Nelfinavir)

8 June, 2007

Recall of Viracept (Nelfinavir)

Pharmaceutical company Roche is taking responsible action with its voluntary recall of the anti-HIV treatment nelfinavir (Viracept), says government drug-funding agency PHARMAC.

Viracept has been withdrawn in New Zealand and internationally because of reports some batches may have been contaminated. Patients taking the drug are being advised to visit their doctor to discuss alternative treatments.

About 20 New Zealanders are currently taking Viracept.

PHARMAC’s Manager, Funding and Procurement Steffan Crausaz says Roche’s recall will minimise risks to patients, and is the sort of action that ought to be taken in the circumstances.

“Roche’s product withdrawal is responsible and shows that manufacturing and supply issues can affect even the largest pharmaceutical manufacturers,” he says.

“While it will cause some short-term disruption for patients, it is in the best long-term interests and a responsible action to take.”

Viracept is one of the class of drugs known as protease inhibitors, drugs that revolutionized the treatment of HIV/AIDS in the 1990s. Five other protease inhibitors are fully funded, including the combination treatment Kaletra.

ENDS

© Scoop Media